GT Biopharma, Inc. (GTBP) Balance Sheet

The contraction in total assets reflects a business model that is consuming its primary capital reserves to fund R&D without achieving a self-sustaining scale. This downward trend suggests that the company's ability to maintain its current clinical trajectory is increasingly dependent on external financing rather than organic growth.

While the current ratio of 3.50 appears superficially healthy, it is heavily influenced by the composition of current assets which are almost entirely cash. Investors should monitor this liquidity closely, as the lack of diversified current assets suggests that any disruption in capital market access would immediately threaten the company's ongoing operations.

The negative equity position observed in early 2025 suggests that the company has periodically faced technical insolvency, necessitating dilutive equity raises to restore a positive book value. This pattern of equity dilution appears to be a structural feature of the company's financing strategy, which may continue to weigh on shareholder value.